These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 26647959)

  • 21. Up-regulation of Bfl-1/A1 via NF-kappaB activation in cisplatin-resistant human bladder cancer cell line.
    Kim JK; Kim KD; Lee E; Lim JS; Cho HJ; Yoon HK; Cho MY; Baek KE; Park YP; Paik SG; Choe YK; Lee HG
    Cancer Lett; 2004 Aug; 212(1):61-70. PubMed ID: 15246562
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adenovirus-mediated LRIG1 expression enhances the chemosensitivity of bladder cancer cells to cisplatin.
    Yan Z; Jiang J; Li F; Yang W; Xie G; Zhou C; Xia S; Cheng Y
    Oncol Rep; 2015 Apr; 33(4):1791-8. PubMed ID: 25695283
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oestrogen promotes tumorigenesis of bladder cancer by inducing the enhancer RNA-eGREB1.
    Ding M; Liu Y; Li J; Yao L; Liao X; Xie H; Yang K; Zhou Q; Liu Y; Huang W; Cai Z
    J Cell Mol Med; 2018 Dec; 22(12):5919-5927. PubMed ID: 30252203
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The inhibitory effect of intravesical fisetin against bladder cancer by induction of p53 and down-regulation of NF-kappa B pathways in a rat bladder carcinogenesis model.
    Li J; Qu W; Cheng Y; Sun Y; Jiang Y; Zou T; Wang Z; Xu Y; Zhao H
    Basic Clin Pharmacol Toxicol; 2014 Oct; 115(4):321-9. PubMed ID: 24646039
    [TBL] [Abstract][Full Text] [Related]  

  • 25. KLF1 Activates RAC3 to Mediate Fatty Acid Synthesis and Enhance Cisplatin Resistance in Bladder Cancer Cells.
    Song L; Xu Q; Chen R; Sun W; Zhan J
    Am J Mens Health; 2024; 18(5):15579883241273305. PubMed ID: 39376007
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The novel inhibitor BRM270 downregulates tumorigenesis by suppression of NF-κB signaling cascade in MDR-induced stem like cancer-initiating cells.
    Mongre RK; Sodhi SS; Ghosh M; Kim JH; Kim N; Park YH; Kim SJ; Heo YJ; Sharma N; Jeong DK
    Int J Oncol; 2015; 46(6):2573-85. PubMed ID: 25872586
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Maspin enhances cisplatin chemosensitivity in bladder cancer T24 and 5637 cells and correlates with prognosis of muscle-invasive bladder cancer patients receiving cisplatin based neoadjuvant chemotherapy.
    Chen J; Wang L; Tang Y; Gong G; Liu L; Chen M; Chen Z; Cui Y; Li C; Cheng X; Qi L; Zu X
    J Exp Clin Cancer Res; 2016 Jan; 35():2. PubMed ID: 26733306
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interleukin-5 enhances the migration and invasion of bladder cancer cells via ERK1/2-mediated MMP-9/NF-κB/AP-1 pathway: involvement of the p21WAF1 expression.
    Lee EJ; Lee SJ; Kim S; Cho SC; Choi YH; Kim WJ; Moon SK
    Cell Signal; 2013 Oct; 25(10):2025-38. PubMed ID: 23770289
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NOV is upregulated and promotes migration and invasion in bladder cancer.
    Chen J; Gao Y; Xu B; Cui X; Xu D
    Tumour Biol; 2014 Jul; 35(7):6749-55. PubMed ID: 24719190
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Androgen receptor activity modulates responses to cisplatin treatment in bladder cancer.
    Kashiwagi E; Ide H; Inoue S; Kawahara T; Zheng Y; Reis LO; Baras AS; Miyamoto H
    Oncotarget; 2016 Aug; 7(31):49169-49179. PubMed ID: 27322140
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recruited T cells promote the bladder cancer metastasis via up-regulation of the estrogen receptor β/IL-1/c-MET signals.
    Tao L; Qiu J; Slavin S; Ou Z; Liu Z; Ge J; Zuo L; Guancial EA; Messing EM; Chang C; Yeh S
    Cancer Lett; 2018 Aug; 430():215-223. PubMed ID: 29684419
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cancer-associated fibroblasts promote cisplatin resistance in bladder cancer cells by increasing IGF-1/ERβ/Bcl-2 signalling.
    Long X; Xiong W; Zeng X; Qi L; Cai Y; Mo M; Jiang H; Zhu B; Chen Z; Li Y
    Cell Death Dis; 2019 May; 10(5):375. PubMed ID: 31076571
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of c-FLIP in cisplatin resistance of human bladder cancer cells.
    Lee S; Yoon CY; Byun SS; Lee E; Lee SE
    J Urol; 2013 Jun; 189(6):2327-34. PubMed ID: 23313194
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MiR-34b-3p Represses the Multidrug-Chemoresistance of Bladder Cancer Cells by Regulating the CCND2 and P2RY1 Genes.
    Tan Y; Zhang T; Zhou L; Liu S; Liang C
    Med Sci Monit; 2019 Feb; 25():1323-1335. PubMed ID: 30778022
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Concurrent blockade of NF-κB and Akt pathways potentiates cisplatin's antitumor activity in vivo.
    Sun H; Zheng X; Wang Q; Yan J; Li D; Zhou Y; Lin Y; Zhang L; Wang X
    Anticancer Drugs; 2012 Nov; 23(10):1039-46. PubMed ID: 22760211
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Downregulation of LAPTM5 suppresses cell proliferation and viability inducing cell cycle arrest at G0/G1 phase of bladder cancer cells.
    Chen L; Wang G; Luo Y; Wang Y; Xie C; Jiang W; Xiao Y; Qian G; Wang X
    Int J Oncol; 2017 Jan; 50(1):263-271. PubMed ID: 27922670
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypoxia-elevated circELP3 contributes to bladder cancer progression and cisplatin resistance.
    Su Y; Yang W; Jiang N; Shi J; Chen L; Zhong G; Bi J; Dong W; Wang Q; Wang C; Lin T
    Int J Biol Sci; 2019; 15(2):441-452. PubMed ID: 30745833
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Suppression of ERβ signaling via ERβ knockout or antagonist protects against bladder cancer development.
    Hsu I; Chuang KL; Slavin S; Da J; Lim WX; Pang ST; O'Brien JH; Yeh S
    Carcinogenesis; 2014 Mar; 35(3):651-61. PubMed ID: 24148819
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FGF2-mediated reciprocal tumor cell-endothelial cell interplay contributes to the growth of chemoresistant cells: a potential mechanism for superficial bladder cancer recurrence.
    Chen Y; Zhu G; Wu K; Gao Y; Zeng J; Shi Q; Guo P; Wang X; Chang LS; Li L; He D
    Tumour Biol; 2016 Apr; 37(4):4313-21. PubMed ID: 26493998
    [TBL] [Abstract][Full Text] [Related]  

  • 40. VEGF-C inhibition reverses resistance of bladder cancer cells to cisplatin via upregulating maspin.
    Zhu H; Yun F; Shi X; Wang D
    Mol Med Rep; 2015 Aug; 12(2):3163-9. PubMed ID: 25936422
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.